TerminatedPhase 2NCT00701870
Study of Telintra for Treatment of Chemotherapy Induced Neutropenia in Patients With Non-Small Cell Lung Cancer
Studying NON RARE IN EUROPE: Non-small cell lung cancer
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Telik
- Principal Investigator
- Gail Brown, MDTelik
- Intervention
- ezatiostat hydrochloride (Telintra®)(drug)
- Enrollment
- 1 target
- Eligibility
- 18 years · All sexes
- Timeline
- 2008 – 2008
Study locations (24)
- Central Hematology Oncology Medical Group, Alhambra, California, United States
- Pacific Cancer Medical Center, Inc., Anaheim, California, United States
- Providence St. Joseph Medical Center, Burbank, California, United States
- St. Jude Heritage Healthcare, Fullerton, California, United States
- Wilshire Oncology Medical Group, La Verne, California, United States
- UCLA Medical Center, Los Angeles, California, United States
- Clinical Trials and Research Associates, Inc., Montebello, California, United States
- North Valley Hematology/Oncology Medical Group, Northridge, California, United States
- Ventura County Hematology-Oncology Specialists, Oxnard, California, United States
- Samsum Clinic, Santa Barbara, California, United States
- Santa Barbara Hematology Oncology Medical Group, Inc., Santa Barbara, California, United States
- Central Coast Medical Oncology Corporation, Santa Maria, California, United States
- Broward Oncology Associates, Fort Lauderdale, Florida, United States
- Nature Coast Clinical Research, Inverness, Florida, United States
- Lakeland Regional Cancer Center, Lakeland, Florida, United States
- +9 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT00701870 on ClinicalTrials.govOther trials for NON RARE IN EUROPE: Non-small cell lung cancer
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE2NCT06878274Post-operative Radiotherapy After Neodjuvant Chemo-immunotherapy and Surgery in Stage III NSCLCCentre hospitalier de l'Université de Montréal (CHUM)
- RECRUITINGPHASE3NCT07251582Effect of Infusion Timing on Pathologic Response to Neoadjuvant Immunotherapy in Resectable Non-Small Cell Lung CancerHunan Province Tumor Hospital
- RECRUITINGPHASE2NCT06946797A Study to Evaluate Two Dosing Regimens of Subcutaneous Nivolumab in Combination With Intravenous Ipilimumab and Chemotherapy in Participants With Previously Untreated Metastatic or Recurrent Non-Small Cell Lung Cancer (NSCLC)Bristol-Myers Squibb
- RECRUITINGPHASE2NCT07086456Combination of Concurrent Chemoradiotherapy With Surufatinib and Tislelizumab in Patients With Locally Advanced Non-Small Cell Lung CancerSun Yat-sen University
- RECRUITINGNANCT07086300Electroacupuncture Combined With PD-1 Inhibitor for Elderly Patients With Advanced NSCLCKong Fanming
- RECRUITINGPHASE2NCT06620835Trial for Local Ablative Treatment (LAT) Optimization in Patients With Advanced Non-Small Cells Lung Cancer (NSCLC) Presenting an Anaplastic Lymphoma Kinase (ALK) Rearrangement Treated by BrigatinibGroupe Francais De Pneumo-Cancerologie
- RECRUITINGPHASE1, PHASE2NCT06922591Study to Evaluate the Safety, Tolerability & Efficacy of TNG462 in Combination in PDAC & NSCLC PatientsTango Therapeutics, Inc.
- RECRUITINGPHASE3NCT07050043Low Dose Nivolumab With Chemotherapy vs Standard Chemotherapy as First-Line Treatment in Advanced or Metastatic NSCLCDr Arvindran A/L Alaga
See all trials for NON RARE IN EUROPE: Non-small cell lung cancer →